Your browser doesn't support javascript.
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases.
Nistri, Riccardo; Barbuti, Elena; Rinaldi, Virginia; Tufano, Laura; Pozzilli, Valeria; Ianniello, Antonio; Marinelli, Fabiana; De Luca, Giovanna; Prosperini, Luca; Tomassini, Valentina; Pozzilli, Carlo.
  • Nistri R; Neurology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • Barbuti E; Neurology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • Rinaldi V; Neurology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • Tufano L; Neurology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • Pozzilli V; Institute of Advanced Biomedical Technologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.
  • Ianniello A; MS Centre, Department of Clinical Neurology, SS. Annunziata University Hospital, Chieti, Italy.
  • Marinelli F; MS Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • De Luca G; MS Centre, Department of Neurology, Fabrizio Spaziani Hospital, Frosinone, Italy.
  • Prosperini L; MS Centre, Department of Clinical Neurology, SS. Annunziata University Hospital, Chieti, Italy.
  • Tomassini V; MS Centre, Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy.
  • Pozzilli C; Institute of Advanced Biomedical Technologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.
Front Neurol ; 12: 765954, 2021.
Article in English | MEDLINE | ID: covidwho-1506524
ABSTRACT

Objective:

To describe a temporal association between COVID-19 vaccine administration and multiple sclerosis (MS) relapses.

Methods:

This case series study was collected in four MS Centres in Central Italy, using data from 16 MS patients who received COVID-19 vaccination and presented both clinically and radiologically confirmed relapses between March and June 2021. We collected patients' relevant medical history, including demographics, MS clinical course, disease-modifying treatment (DMT) received (if applicable), and data from MRI scans obtained after the COVID-19 vaccination.

Results:

Three out of 16 patients received a diagnosis of MS with a first episode occurring after COVID-19 vaccination; 13 had already a diagnosis of MS and, among them, 9 were on treatment with DMTs. Ten patients received BNT162b2/Pfizer-BioNTech, 2 patients mRNA-1273/Moderna, and 4 patients ChAdOx1 nCoV-19/AstraZeneca. All MS relapses occurred from 3 days to 3 weeks after receiving the first dose of the COVID-19 vaccination or the booster. All patients had evidence of radiological activity on MRI.

Discussion:

Clinical and radiological findings in these cohort of MS patients confirmed disease re/activation and suggested a temporal association between disease activity and COVID-19 vaccination. The nature of this temporal association, whether causative or incidental, remains to be established.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Front Neurol Year: 2021 Document Type: Article Affiliation country: Fneur.2021.765954

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Front Neurol Year: 2021 Document Type: Article Affiliation country: Fneur.2021.765954